Last updated on July 2019

Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer

Brief description of study

This randomized phase III trial studies how well stereotactic body radiation therapy works compared to intensity-modulated radiation therapy in treating patients with stage IIA-B prostate cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Stereotactic body radiation therapy may work better in treating patients with prostate cancer.

Detailed Study Description


I. To determine whether stereotactic body radiation therapy (SBRT) can be shown to be superior to hypofractionated intensity-modulated radiation therapy (IMRT) in terms of genitourinary (GU) and gastrointestinal (GI) toxicity by having fewer patients that experience a minimal important decline (MID) in urinary irritation/obstructive and bowel Health Related Quality of Life (HRQOL) as measured by Expanded Prostate Cancer Index Composite (EPIC)-26 at 24 months post completion of therapy.


I. To determine if SBRT (5 fractions of 7.25 Gy) is superior to hypofractionated IMRT (28 fractions of 2.5 Gy) as measured by disease free survival (DFS).

II. To determine whether SBRT can be shown to be superior to hypofractionated IMRT at 12 and 24 months post completion of therapy in terms of HRQOL by having fewer patients that experience a minimal important decline (MID) bowel (12 months only) sexual, hormonal, urinary irritation/obstructive (12 months only) and in urinary incontinence HRQOL as measured by EPIC-26.

III. To determine if SBRT (5 fractions of 7.25 Gy) is superior to hypofractionated IMRT (28 fractions of 2.5 Gy) as measured by biochemical failure, overall survival, local failure, prostate cancer specific survival, and distant metastases.

IV. To determine if prostate imaging-reporting and data system (PIRADS)version (v)2 = 4/5 disease is predictive for biochemical failure.


I. To determine whether a potentially more expensive therapy, SBRT, would be cost-effective than standard hypofractionated IMRT as measured by the European Quality of Life Five Dimension Five Level Scale Questionnaire (EQ-5D-5L).

II. To determine if disease characteristics captured on MRI can be used to predict which patients will respond to SBRT versus hypofractionated IMRT.

III. Collect specimens for future translational research analyses.

OUTLINE: Patients are randomized into 1 of 2 arms.

ARM I: Patients undergo IMRT once daily for 5 fractions per week for 28 fractions over less than 32 business days.

ARM II: Patients undergo SBRT at least every other day for 2-3 fractions per week for 5 fractions over less than 12 business days.

After completion of study treatment, patients are followed up every 6-12 months until death or study termination.

Clinical Study Identifier: NCT03367702

Find a site near you

Start Over

Piedmont Hospital

Atlanta, GA United States
  Connect »

Geauga Hospital

Chardon, OH United States
  Connect »

Hillcrest Hospital Cancer Center

Mayfield Heights, OH United States
  Connect »

Self Regional Healthcare

Greenwood, SC United States
  Connect »

Decatur Memorial Hospital

Decatur, IL United States
  Connect »

Fresno Cancer Center

Fresno, CA United States
  Connect »

Rohnert Park Cancer Center

Rohnert Park, CA United States
  Connect »

Kaiser Permanente Cancer Treatment Center

South San Francisco, CA United States
  Connect »

Yale University

New Haven, CT United States
  Connect »

Beebe Health Campus

Rehoboth Beach, DE United States
  Connect »

Piedmont Fayette Hospital

Fayetteville, GA United States
  Connect »

Crossroads Cancer Center

Effingham, IL United States
  Connect »

Carle Cancer Center

Urbana, IL United States
  Connect »

Saint Joseph Mercy Hospital

Ann Arbor, MI United States
  Connect »

Weisberg Cancer Treatment Center

Farmington Hills, MI United States
  Connect »

McLaren-Greater Lansing

Lansing, MI United States
  Connect »

McLaren Cancer Institute-Macomb

Mount Clemens, MI United States
  Connect »

McLaren-Port Huron

Port Huron, MI United States
  Connect »

Regions Hospital

Saint Paul, MN United States
  Connect »

Saint Francis Medical Center

Cape Girardeau, MO United States
  Connect »

Lovelace Radiation Oncology

Albuquerque, NM United States
  Connect »

Mary Imogene Bassett Hospital

Cooperstown, NY United States
  Connect »

North Coast Cancer Care

Sandusky, OH United States
  Connect »

Bryn Mawr Hospital

Bryn Mawr, PA United States
  Connect »

Geisinger Medical Center

Danville, PA United States
  Connect »

Delaware County Memorial Hospital

Drexel Hill, PA United States
  Connect »

Paoli Memorial Hospital

Paoli, PA United States
  Connect »

Lankenau Medical Center

Wynnewood, PA United States
  Connect »

Texas Cancer Center

Abilene, TX United States
  Connect »

Deke Slayton Cancer Center

Webster, TX United States
  Connect »

Aurora BayCare Medical Center

Green Bay, WI United States
  Connect »

Ascension Mercy Hospital

Oshkosh, WI United States
  Connect »

UHHS-Westlake Medical Center

Westlake, OH United States
  Connect »